Select location for product information:

Drug Utilisation Study

Drug Utilisation Study

Flag of the United Kingdom

UK Prescribing Information

Flag of Ireland

Ireland Prescribing Information

Proveca is conducting a Drug Utilisation Study (DUS) to assess the value of the materials provided with Sialanar® (400mcg/ml glycopyrronium bromide equivalent to 320mcg/ml glycopyrronium) in supporting the safe use of the product. These include:

  • checklist for healthcare professional
  • reminder card for caregivers

The study requires participants to enter information about their patients receiving Sialanar®, every 3 months until the patient completes 12 months of treatment or leaves the study (whichever is sooner).

If you would like to take part in the study, please click on the attached link www.sialanarDUS.com for more information and to register your interest.

Please see information below to report adverse events in the UK

Adverse events should be reported. Reporting forms and information can be found at: www.mhra.gov.uk/yellowcard.
Adverse events should also be reported to Proveca Limited.
Phone: 0333 200 1866 E-mail: medinfo@proveca.com

Please see information below to report adverse events in the Republic of Ireland

Adverse events should be reported. Reporting forms and information can be found at: www.hpra.ie.
Adverse events should also be reported to Proveca Limited.
Phone: +44 333 200 1866 E-mail: medinfo@proveca.com

UK-SIA-23-0100
Updated June 2023